Benefits:
- Wide range of HLA sub-types
- Broad coverage of pathogens
- Optimized for populations with diverse ethnic background
- High purity for clinical trial immune monitoring
- CMV-free version (EFX Ultra SuperStim Pool)
- MHC-I & MHC-II specific subsets
Together with our collaborators at Pfizer we will present experimental data confirming the superiority of the CEFX Ultra SuperStim concept at the upcoming AAI - Immunology 2018 Meeting. If you are interested, please visit our Booth # 207 and Poster # 120.15, or contact us to receive a copy of the poster after the conference.